Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases

BMC Cancer

Research Article

Adam Pawinski¹  Astrid Dalhaug¹  Ellinor Haukland¹  Carsten Nieder² 

[1] Department of Internal Medicine - Division of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;Department of Internal Medicine - Division of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway;Institute of Clinical Medicine, Faculty of Medicine, University of Tromsø, Tromsø, Norway;

关键词: Prostate Cancer;    Bone Metastasis;    Androgen Deprivation Therapy;    Metastatic Prostate Cancer;    Severe Thrombocytopenia;   

DOI  :  10.1186/1471-2407-10-284

 received in 2009-11-19, accepted in 2010-06-13,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundThe purpose of this study was to determine the incidence, risk factors and prognostic impact of anaemia and thrombocytopenia in patients with bone metastases (BM) from prostate cancer.MethodsRetrospective cohort study including 51 consecutive patients treated at a community hospital. Twenty-nine patients (57%) received taxotere after diagnosis of BM.ResultsHaemoglobin (Hb) ≤ 12.0 g/dL at BM detection was associated with shorter overall survival. During follow-up, 25 patients (49%) experienced episodes with Hb < 10 g/dL unrelated to side effects of cancer therapy. Fifteen patients required red blood cell transfusion. Median time from diagnosis of BM to Hb < 10 g/dL was 23 months. Median survival from Hb < 10 g/dL was 5.4 months. There was no factor predicting for Hb < 10 g/dL. Five patients (10%) developed thrombocyte (Trc) count <50 × 109/L. All of these had previously received blood transfusion. Median interval from Hb < 10 g/dL to Trc < 50 × 109/L was 2.5 months. Survival after thrombocytopenia was short (3 weeks to 4 months). Haematuria and subdural haematoma were among the causes of death.ConclusionsWe found high rates of significant bone marrow failure in treatment-refractory patients. Both Hb < 10 g/dL and Trc < 50 × 109/L predict for unfavourable survival.

【 授权许可】

CC BY   
© Nieder et al; licensee BioMed Central Ltd. 2010